Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

[1]  A. Heiligenhaus,et al.  Adalimumab in Patients with Active Noninfectious Uveitis. , 2016, The New England journal of medicine.

[2]  L. Biard,et al.  Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network , 2016, Arthritis & rheumatology.

[3]  A. Dick,et al.  Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. , 2016, Ophthalmology.

[4]  G. Jaffe,et al.  SAT0523 Adalimumab in Patients with Active, Non-Infectious Uveitis Requiring High-Dose Corticosteroids: the Visual-1 Trial , 2015 .

[5]  A. Bar,et al.  Long-term clinical outcome and causes of vision loss in patients with uveitis. , 2014, Ophthalmology.

[6]  E. Héron,et al.  Efficacy and safety of anti TNFα in non‐infectious uveitis: a multi‐center retrospective study , 2014 .

[7]  P. Robert,et al.  Eswab® transport media and 16S RNA PCR in the microbiological diagnosis of infectious keratitis , 2014 .

[8]  R. V. Van Gelder,et al.  Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. , 2014, Ophthalmology.

[9]  J. Rosenbaum,et al.  Update on the use of systemic biologic agents in the treatment of noninfectious uveitis , 2014, Biologics : targets & therapy.

[10]  Yu-lan Jin.  Immunosuppressive therapy for noninfectious uveitis , 2014 .

[11]  S. Androudi,et al.  Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. , 2013, Ophthalmology.

[12]  Justine R. Smith,et al.  Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial , 2013, British Journal of Ophthalmology.

[13]  G. Burmester,et al.  Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease , 2012, Annals of the rheumatic diseases.

[14]  J. F. Arevalo,et al.  Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. , 2012, Ophthalmology.

[15]  M. Mochizuki,et al.  Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. , 2012, Archives of ophthalmology.

[16]  A. Heiligenhaus,et al.  Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[17]  Larry D Hubbard,et al.  Evaluation of the age-related eye disease study clinical lens grading system AREDS report No. 31. , 2010, Ophthalmology.

[18]  Justine R. Smith,et al.  Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. , 2009, Archives of ophthalmology.

[19]  J. Callejas-Rubio,et al.  Adalimumab therapy for refractory uveitis: a pilot study. , 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[20]  F. J. Romero,et al.  Adalimumab therapy for refractory uveitis: a pilot study. , 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[21]  K. Aalto,et al.  Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. , 2007, Rheumatology.

[22]  C. Rabinovich,et al.  Use of tumor necrosis factor inhibitors in uveitis , 2007, Current opinion in rheumatology.

[23]  Douglas A Jabs,et al.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. , 2005, American journal of ophthalmology.

[24]  G. Horneff,et al.  Etanercept and uveitis in patients with juvenile idiopathic arthritis. , 2005, Rheumatology.

[25]  Justine R. Smith,et al.  Management of sight-threatening uveitis: new therapeutic options. , 2005, Drugs.

[26]  P. Murray,et al.  Degree, duration, and causes of visual loss in uveitis , 2004, British Journal of Ophthalmology.

[27]  J. Beckham,et al.  Disease severity in rheumatoid arthritis: Relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures , 1992, Journal of Clinical Immunology.

[28]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[29]  N. Waheed,et al.  Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. , 2003, Archives of ophthalmology.

[30]  R. V. Van Gelder,et al.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. , 2000, American journal of ophthalmology.

[31]  P. Villiger,et al.  Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. , 1997, The Journal of rheumatology.

[32]  A. Rothova,et al.  Causes and frequency of blindness in patients with intraocular inflammatory disease. , 1996, The British journal of ophthalmology.

[33]  M. Feldmann,et al.  Cytokines in autoimmunity. , 1992, Current opinion in immunology.

[34]  R. Nussenblatt,et al.  Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. , 1985, Ophthalmology.

[35]  Club Jules Gonin,et al.  Graefe's archive for clinical and experimental ophthalmology , 1982 .